Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn Pharmaceuticals, a developer of therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs, has concluded patient recruitment in a Phase IIb trial to evaluate Serdaxin as a treatment for major depressive disorder (MDD).
Subscribe to our email newsletter
In the trial, the company has recruited around 300 patients at around 40 sites in the US.
The Phase IIb trial, which is a randomized, double blind and placebo controlled trial, expects to release preliminary results in late 2011.
The primary efficacy endpoint of the study is the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS)
Rexahn president and chief operating officer Rick Soni said they are excited by the speed at which they have completed enrollment in our Phase IIb trial for Serdaxin and believe that this further validates the current unmet need for an effective treatment for major depressive disorder.
"We look forward to completing the trial and announcing preliminary results before the end of the year," Soni said.